Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease
Phase 1 trial shows promising survival and tolerability in older adults with relapsed/refractory disease, highlighting cytokines and immune reconstitution.
Key Points
Survival rates reached 55% at 2 years with full donor chimerism achieved in all patients treated.
Phase 1 trial focused on TMLI with fludarabine-melphalan conditioning for high-risk relapsed/refactory disease.
Adverse events included dose-dependent GI toxicity and febrile neutropenia, primarily at higher doses.
Found promising indications for immune reconstitution and cytokine levels correlating with dosing outcomes.